MFAP4 Antibodies Block Integrin Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for vascular proliferative diseases, such as restenosis after percutaneous coronary interventions, lack effective medicaments to inhibit vascular smooth muscle cell proliferation and migration, and there is a need for treatments that can prevent or treat cardiovascular and vascular eye disorders like AMD and DR.
Innovation Solution
Development of antibodies that specifically block the integrin interacting motif in human microfibrillar-associated protein 4 (MFAP4), which are used to inhibit the interaction between MFAP4 and integrin receptors, thereby preventing or treating cardiovascular proliferative diseases, allergic asthma, and vascular eye disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If percutaneous coronary intervention (PCI) is performed to treat ischemic heart diseases, then the invasiveness is reduced and patient recovery is improved, but restenosis occurs in 30-45% of patients within several months after surgery
Solution Approach 1:
The patent uses antibodies as intermediary molecules that specifically bind to MFAP4, blocking its interaction with integrin receptors on vascular smooth muscle cells. This intermediary approach prevents the signaling pathway that leads to restenosis without requiring surgical intervention, thus maintaining the low invasiveness of PCI while improving restenosis prevention efficacy.
Solution Approach 2:
The patent extracts and targets the specific molecular mechanism (MFAP4-integrin interaction) that drives restenosis after PCI. By isolating this key pathogenic pathway and blocking it with antibodies, the treatment addresses the root cause of restenosis while preserving the benefits of minimally invasive PCI procedures.
2Reliability
If vascular smooth muscle cell proliferation and migration are inhibited to prevent restenosis, then restenosis and neointima formation are reduced, but vascular remodeling processes are affected
Solution Approach 1:
The patent applies local quality by specifically targeting the MFAP4-integrin interaction pathway in vascular smooth muscle cells, rather than broadly inhibiting all cellular proliferation and migration processes. This localized approach prevents restenosis while preserving other essential vascular remodeling functions that do not depend on this specific pathway.
Solution Approach 2:
The antibodies serve as intermediaries that selectively block the MFAP4-integrin signaling pathway, allowing precise modulation of vascular smooth muscle cell behavior. This intermediary mechanism enables differentiation between pathological proliferation (restenosis) and physiological remodeling processes.
3Reliability
If MFAP4 interaction with integrin receptors is blocked to prevent vascular smooth muscle cell activation, then proliferation and migration are reduced, but the mechanism of action needs to be highly specific to avoid off-target effects
Solution Approach 1:
The patent segments the complex integrin family into specific subtypes (αvβ3 and αvβ5) and develops antibodies that target MFAP4's interaction with these particular receptors. This segmentation approach allows selective inhibition of pathological pathways while preserving other integrin-mediated functions that are essential for normal vascular physiology.
Solution Approach 2:
The antibodies act as highly specific intermediaries that bridge MFAP4 and block its binding to integrin receptors with precise molecular recognition. This intermediary mechanism ensures high specificity through antibody-antigen binding, avoiding off-target effects while effectively controlling vascular smooth muscle cell activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively delay and regulate the activation, proliferation, and migration of vascular smooth muscle cells, reducing neointima formation and inflammatory infiltration, thus addressing the challenges of restenosis and vascular remodeling.
Implementation Method 1
antibodies, in particular monoclonal, that bind human Microfibrillar-associated protein 4 (MFAP4)
Implementation Method 2
specifically blocks the integrin interacting motif in human microfibrillar-associated protein 4 (MFAP4)
Data Source
Figure 1
Figure 2A~2G
Figure 3A~3F
AI summary
Microfibrillar-associated protein 4 (MFAP4) binding antibodies are provided to prevent or to inhibit the proliferation of vascular smooth muscle cells and neointima formation in blood vessels. Furthermore, there are provided antibodies that effectively inhibit remodelling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels. The provided antibodies block the interaction between MFAP4 and integrin receptors.